Загрузка...
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
INTRODUCTION: Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% of patients obtaining complete hematologic respo...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2899790/ https://ncbi.nlm.nih.gov/pubmed/20694077 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|